All News
Difficult to Manage Axial Spondyloarthritis
Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.
Read Article
Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Richard Conway RichardPAConway ( View Tweet)
Stone et al. Phase 3 RCT B-cell depletion with CD19 targeting agent Inebilizumab in IgG4-RD. HR 0.13 (0.06, 0.28) for flare. @RheumNow #ACR24 Abstr#0775 https://t.co/Kd4Xmoc5e6 https://t.co/Al6gOA1F8K
Richard Conway RichardPAConway ( View Tweet)
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs?
≥5% weight loss, after taking a med, led to better disease activity & QoL
Data may inform RCTs to explore effect of these meds in RMDs
Ab0845 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Results from MANDARA- #EGPA pts treated with benralizumab or mepolizumab
Eosinophil-targeting biologics rapidly control airway- & non-airway-related manifestations
Few pts had worsening of disease that progressed to organ damage over 52W
Ab0828 #ACR24 @RheumNow https://t.co/hIn9iyNVWQ
Mrinalini Dey DrMiniDey ( View Tweet)
Ab#0458 #ACR24
10 year outcomes of 176 patients with seroneg RA
32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1)
40 (23%) had drug-free remission
30 (17%) started b/tsDMARD
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE
Richard Conway RichardPAConway ( View Tweet)
Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE
Richard Conway RichardPAConway ( View Tweet)
Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate
All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission
#ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO
Mike Putman EBRheum ( View Tweet)
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/2t8xcYJ3UV
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
This is likely an oversimplification, but I've been looking for exactly this diagram
Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition
@EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No?
@rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3
Mike Putman EBRheum ( View Tweet)
FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC
Dr. John Cush RheumNow ( View Tweet)
De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL
Richard Conway RichardPAConway ( View Tweet)
De Lorenzis et al. MMF in LcSSc. Target Trial Emulation. 1435 patients. Incidence vasodilator treatment escalation over 41 months, 1/100py in MMF vs 7.3/100py in controls. @RheumNow #ACR24 Abstr#0688 https://t.co/D3qTUHyIIc https://t.co/6azvaS0ElL
Richard Conway RichardPAConway ( View Tweet)
The risk of discontinuing first line biologics was twice higher in non-radiographic female patients compared to males. Abstr#0572 @RheumNow #ACR24 https://t.co/1tQUhsbqUu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz
Richard Conway RichardPAConway ( View Tweet)
Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz
Richard Conway RichardPAConway ( View Tweet)
Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0
Richard Conway RichardPAConway ( View Tweet)
Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0
Richard Conway RichardPAConway ( View Tweet)
Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm
Richard Conway RichardPAConway ( View Tweet)